Alexion Pharmaceuticals, Inc.

Westfaelische Wilhelms-universitaet Muenster

Inozyme Pharma, Inc.

Yan Yan

Susan Faas Mcknight

Roxanne Cofiell

Anjli Kukreja

Russell P Rother

Krystin A Bedard

Susan Faas McKnight

Andre Marozsan

Kim Lynette Askew

Anumeha Shah

Herman Griffin

Yvonne Nitschke

Ashmita Saigal

Frank Rutsch

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Atypical hemolytic uremic syndrome (AHUS) biomarker proteins

The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.

Methods of treating myointimal proliferation

The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.

Therapeutic methods using anti-CD200 antibodies

Atypical hemolytic uremic syndrome (aHUS) biomarker proteins

The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient.

Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies

Growing community of inventors

Cheshire, CT, United States of America

Yan Yan